Details of the Drug

General Information of Drug (ID: DMKOXFE)

Drug Name

Doxylamine

Synonyms

Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline

Indication

Disease Entry	ICD 11	Status	REF
Morning sickness	SC00	Approved	[1], [2]

Therapeutic Class

Hypnotics and Sedatives

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

270.37

Topological Polar Surface Area (xlogp)

2.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is readily absorbed from the gastrointestinal tract [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 hours [4]
Metabolism: The drug is metabolized via the hepatic [3]

Chemical Identifiers

Formula: C17H22N2O
IUPAC Name: N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
Canonical SMILES: CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
InChI: InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
InChIKey: HCFDWZZGGLSKEP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3162
ChEBI ID: CHEBI:51380
CAS Number: 469-21-6
DrugBank ID: DB00366
TTD ID: D0Y2LR
ACDINA ID: D00216

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[5], [6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Morning sickness

ICD Disease Classification

SC00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Doxylamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive CNS depression effects by the combination of Doxylamine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[15]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[16]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[17]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[17]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Tacrine	DM51FY6	Moderate	Antagonize the effect of Doxylamine when combined with Tacrine.	Alzheimer disease [8A20]	[18]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Memantine.	Alzheimer disease [8A20]	[16]
Galantamine	DMEO794	Moderate	Antagonize the effect of Doxylamine when combined with Galantamine.	Alzheimer disease [8A20]	[18]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Doxylamine when combined with Rivastigmine.	Alzheimer disease [8A20]	[18]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Doxylamine when combined with Donepezil.	Alzheimer disease [8A20]	[18]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[16]
Promazine	DMZAL7W	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Promazine.	Appearance/behaviour symptom [MB23]	[16]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[16]
Linezolid	DMGFPU2	Major	Additive anticholinergic effects by the combination of Doxylamine and Linezolid.	Bacterial infection [1A00-1C4Z]	[15]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Cariprazine.	Bipolar disorder [6A60]	[16]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Doxylamine and Loperamide.	Bowel habit change [ME05]	[19]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Doxylamine when combined with Acetylcholine.	Cataract [9B10]	[20]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[21]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[21]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[21]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Doxylamine and Olopatadine.	Conjunctiva disorder [9A60]	[22]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Doxylamine and Ethanol.	Cystitis [GC00]	[22]
Trimipramine	DM1SC8M	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Trimipramine.	Depression [6A70-6A7Z]	[16]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[16]
Imipramine	DM2NUH3	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Imipramine.	Depression [6A70-6A7Z]	[16]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Nortriptyline.	Depression [6A70-6A7Z]	[16]
Selegiline	DM6034S	Major	Additive anticholinergic effects by the combination of Doxylamine and Selegiline.	Depression [6A70-6A7Z]	[15]
Isocarboxazid	DMAF1NB	Major	Additive anticholinergic effects by the combination of Doxylamine and Isocarboxazid.	Depression [6A70-6A7Z]	[15]
Tranylcypromine	DMGB5RE	Major	Additive CNS depression effects by the combination of Doxylamine and Tranylcypromine.	Depression [6A70-6A7Z]	[15]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Doxylamine and OPC-34712.	Depression [6A70-6A7Z]	[16]
Phenelzine	DMHIDUE	Major	Additive CNS depression effects by the combination of Doxylamine and Phenelzine.	Depression [6A70-6A7Z]	[15]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Amoxapine.	Depression [6A70-6A7Z]	[16]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Doxepin.	Depression [6A70-6A7Z]	[16]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Maprotiline.	Depression [6A70-6A7Z]	[16]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Doxylamine and Esketamine.	Depression [6A70-6A7Z]	[23]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Hyoscyamine.	Digestive system disease [DE2Z]	[16]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Mepenzolate.	Digestive system disease [DE2Z]	[16]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Oxybutynine.	Discovery agent [N.A.]	[16]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Meclizine.	Dizziness and giddiness [MB48]	[16]
Trihexyphenidyl	DMB19L8	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Trihexyphenidyl.	Dystonic disorder [8A02]	[16]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Doxylamine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[16]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Solifenacin.	Functional bladder disorder [GC50]	[16]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Tolterodine.	Functional bladder disorder [GC50]	[16]
Darifenacin	DMWXLYZ	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Darifenacin.	Functional bladder disorder [GC50]	[16]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Propantheline.	Gastric ulcer [DA60]	[16]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Doxylamine when combined with Isoflurophate.	Glaucoma [9C61]	[20]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Doxylamine and Brimonidine.	Glaucoma [9C61]	[25]
Procarbazine	DMIK367	Major	Additive CNS depression effects by the combination of Doxylamine and Procarbazine.	Hodgkin lymphoma [2B30]	[15]
Potassium chloride	DMMTAJC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Doxylamine and Potassium chloride.	Hypo-kalaemia [5C77]	[26]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[16]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Amantadine.	Influenza [1E30-1E32]	[27]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Propiomazine.	Insomnia [7A00-7A0Z]	[16]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Doxylamine and ITI-007.	Insomnia [7A00-7A0Z]	[16]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Clidinium.	Irritable bowel syndrome [DD91]	[16]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Dicyclomine.	Irritable bowel syndrome [DD91]	[16]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Doxylamine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[18]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Doxylamine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[28]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Doxylamine and Lasmiditan.	Migraine [8A80]	[29]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Doxylamine and Thalidomide.	Multiple myeloma [2A83]	[30]
Ozanimod	DMT6AM2	Major	Additive anticholinergic effects by the combination of Doxylamine and Ozanimod.	Multiple sclerosis [8A40]	[31]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Phenindamine.	Nasopharyngitis [CA00]	[16]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Dimenhydrinate.	Nausea/vomiting [MD90]	[16]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Prochlorperazine.	Nausea/vomiting [MD90]	[16]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Promethazine.	Nausea/vomiting [MD90]	[16]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Cyclizine.	Nausea/vomiting [MD90]	[16]
Thiethylperazine	DMU3IET	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Thiethylperazine.	Nausea/vomiting [MD90]	[16]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Doxylamine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[32]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Doxylamine and Apraclonidine.	Optic nerve disorder [9C40]	[25]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Doxylamine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[33]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Flavoxate.	Pain [MG30-MG3Z]	[16]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Biperiden.	Parkinsonism [8A00]	[16]
Procyclidine	DMHFJDT	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Procyclidine.	Parkinsonism [8A00]	[16]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Orphenadrine.	Parkinsonism [8A00]	[16]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Methylscopolamine.	Peptic ulcer [DA61]	[16]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[16]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[16]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[16]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[16]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Quetiapine.	Schizophrenia [6A20]	[16]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Mesoridazine.	Schizophrenia [6A20]	[16]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Thioridazine.	Schizophrenia [6A20]	[16]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Aripiprazole.	Schizophrenia [6A20]	[16]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Iloperidone.	Schizophrenia [6A20]	[16]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Paliperidone.	Schizophrenia [6A20]	[16]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Loxapine.	Schizophrenia [6A20]	[16]
Haloperidol	DM96SE0	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Haloperidol.	Schizophrenia [6A20]	[16]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Perphenazine.	Schizophrenia [6A20]	[16]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Molindone.	Schizophrenia [6A20]	[16]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Chlorpromazine.	Schizophrenia [6A20]	[16]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Thiothixene.	Schizophrenia [6A20]	[16]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Trifluoperazine.	Schizophrenia [6A20]	[16]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Risperidone.	Schizophrenia [6A20]	[16]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Asenapine.	Schizophrenia [6A20]	[16]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Pimozide.	Schizophrenia [6A20]	[16]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Doxylamine and Tizanidine.	Tonus and reflex abnormality [MB47]	[34]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Atropine.	Unspecific substance harmful effect [NE6Z]	[16]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[16]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[16]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[16]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[17]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[16]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[16]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[16]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Doxylamine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[16]
-----------


⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sucralose	E00370	71485	Flavoring agent
Tannic acid	E00517	16129778	Antioxidant
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Magnesium stearate	E00208	11177	lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Doxylamine 5 mg tablet	5 mg	Chewable Tablet	Oral
Doxylamine 25 mg tablet	25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7171).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040167.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22.
6	Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology. 2004 Oct;72(2):92-8.
7	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
8	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
9	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
10	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
11	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
12	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
13	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
14	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
17	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
18	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
19	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
20	Multum Information Services, Inc. Expert Review Panel.
21	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
22	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
23	Cerner Multum, Inc. "Australian Product Information.".
24	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
25	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
26	Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
27	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
28	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
29	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
30	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
31	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
32	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
33	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
34	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.